Key Takeaways Altimmune advances pemvidutide into a crowded MASH field with phase III start planned in 2026.ALT highlights dual glucagon/GLP-1 biology and tolerability as key differentiation vs rivalsALT's 2026 catalysts include AUD data and ALD progress, alongside rising funding needsAltimmune (ALT) is pushing pemvidutide into one of biotech’s most competitive indications: metabolic dysfunction-associated steatohepatitis (MASH). The company argues its balanced 1:1 glucagon/GLP-1 dual receptor agonist can d ...